<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358683</url>
  </required_header>
  <id_info>
    <org_study_id>C87069</org_study_id>
    <secondary_id>RPCE06G0406</secondary_id>
    <nct_id>NCT00358683</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease</brief_title>
  <official_title>Open Label Long Term Clinical Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87055 Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      The primary aim of this study is allow the patients suffering from Crohn's disease , who both
      completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from
      the treatment, to receive treatment with certolizumab pegol until the drug is available for
      the Crohn's disease indication in Greece.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2007</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For ethical reasons, provide the opportunity for patients &gt; 18 years suffering from Crohn's disease who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizum</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events reported by the patients during the long-term treatment period of the study.</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Crohn's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab pegol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Crohn's disease diagnosis

          -  Patients having completed the treatment period of study C87055 (previously treated
             with infliximab) and benefited from the study treatment, as per investigatior's
             discretion.

        Exclusion Criteria:

          -  Subject withdrawn prematurely from C87055 study.

          -  Subject who received treatment other than certolizumab pegol and other than
             medications permitted in C87055 study.

          -  Female patients of childbearing age who are NOT practicing (in the Investigator's
             opinion) effective birth control. All female patients must test negative on a serum
             pregnancy test before study entry and negative on urine testing immediately before
             every certolizumab pegol administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>George Syrmalis, M.D. M.Sc. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2006</study_first_submitted>
  <study_first_submitted_qc>July 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2006</study_first_posted>
  <last_update_submitted>May 25, 2012</last_update_submitted>
  <last_update_submitted_qc>May 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <keyword>certolizunab pegol</keyword>
  <keyword>long term safety follow-up</keyword>
  <keyword>Chrohn's disease</keyword>
  <keyword>infliximab failures patients</keyword>
  <keyword>Greek population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

